FindTrial
Sign In

The Study for Efficacy of Adalimumab Maintenance Therapy Initiated Following Resection of Active Lesions in Crohn's Disease Patients

The Study for Efficacy of Adalimumab Maintenance Therapy Initiated Following Resection of Active Lesions in Crohn's Disease Patients - The Efficacy of Adalimumab Maintenance Therapy for Post-Operative Crohn's Disease

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000009284
Enrollment
20
Registered
2012-11-20
Start date
2012-11-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

adalimumab injected immediately(within 3months) after surgical removal Crohn&#39
s disease lesions(intestinal resection). Inject SC 160mg,80mg,40mg in every other week.

Sponsors

Sakura Medical Center,Toho university
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients after surgical removal of Crohn's disease lesions(intestinal resection) patients enrolled endoscopy 6months and 12months after surgery

Exclusion criteria

Exclusion criteria: 1the patient of contraindication for adalimumab 2pregnancy 3the patient who is short bowel syndrome 4the patient who is not able to calculate CDAI 5the patient with stoma 6the case which is hard to get the patient's consent 7the patient who was judged for insuitable by responsibility doctor

Design outcomes

Primary

MeasureTime frame
remission maintenance rate of adalimumab maintenance therapy ,evaluated by CDAI score 12months after intestinal resection.—

Secondary

MeasureTime frame
remission maintenance rate 6months and 12months after intestinal resection, evaluated by CDAI score and C-reactive protein. remission maintenae rate 6months and 12months after intestinal resection, evaluated by endoscopic score(Rutgeerts score)—

Countries

Japan

Contacts

Public ContactAkihiro Yamada

Sakura Medical Center,Toho University Internal medicine

taro-dog@sakura.med.toho-u.ac.jp043-462-8811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026